Dark Adaptation in Participants With Age-Related Macular Degeneration
NCT03225131 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 57
Last updated 2026-04-24
Summary
Background:
Macular degeneration can cause permanent loss of central vision. This vision is important for seeing details. Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 55 in the United States. Researchers want to follow people with AMD to study the early to middle stages of the disease.
Objective:
To follow for another 5 years participants who completed NIH study 11-EI-0147.
Eligibility:
Participant was enrolled in and completed study 11-EI-0147.
Design:
Participants will have at least 6 study visits over 5 years. Each visit takes about 5 hours.
At visit 1, participants will be asked about their medical and eye disease history. They will have an eye exam. The exam will test vision, eye pressure, and eye movements. The pupil will be dilated with eye drops.
Participants will have baseline exams. These include a health history and questions about problems that affect their eyes under different lighting. They will answer these questions each year.
At each visit, participants will have some or all of these tests:
Eye exam
Dark adaptation protocol. This measures how fast the eyes recover when exposed to decreasing levels of light. The pupil will be dilated with eye drops. Participants will sit in front of a metal box with a camera inside. They will push a button when they see a light in the machine.
View a bright background light for 5 minutes. After the light is turned off participants will push a button when a blue or red light is seen.
Sit in the dark for about 30 minutes. Participants will push a button when they see a blue or red light.
Conditions
- Age-Related Macular Degeneration
Sponsors & Collaborators
-
National Eye Institute (NEI)
lead NIH
Principal Investigators
-
Emily Y Chew, M.D. · National Eye Institute (NEI)
Eligibility
- Min Age
- 50 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-06-16
- Primary Completion
- 2033-12-31
- Completion
- 2033-12-31
Countries
- United States
Study Locations
More Related Trials
-
Functionally Validated Structural Endpoints for Early AMD
NCT04112667 ·Status: COMPLETED
-
Investigating Age-Related Macular Degeneration
NCT00342251 ·Status: COMPLETED
-
The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration
NCT03492853 ·Status: COMPLETED
-
Age-Related Eye Disease Study (AREDS) Follow-Up
NCT00594672 ·Status: ACTIVE_NOT_RECRUITING
-
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
NCT00346060 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Macular Pigment Augmentation on Dark Adaptation
NCT00478439 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients
NCT06582511 ·Status: ACTIVE_NOT_RECRUITING
-
Effects of Sun Filters on Age-related Macular Degeneration in People With Lens Implants
NCT00487838 ·Status: WITHDRAWN
-
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
NCT03478878 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Natural History, Pathogenesis, and Outcome of Ocular Disorders
NCT02821767 ·Status: RECRUITING
-
Oxidative Stress in Patients With Age-Related Macular Degeneration
NCT00465400 ·Status: COMPLETED
-
The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)
NCT02438111 ·Status: UNKNOWN
-
Rod and Cone Mediated Function in Retinal Disease
NCT02617966 ·Status: RECRUITING
-
Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)
NCT04278300 ·Status: COMPLETED
-
"Night Vision and Carotenoids"
NCT04741763 ·Status: COMPLETED ·Phase: NA
-
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
NCT01528605 ·Status: COMPLETED ·Phase: NA
-
Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration
NCT05005884 ·Status: UNKNOWN ·Phase: PHASE1
-
The Influence of Lutein Supplements on Age-related Macular Degeneration
NCT01042860 ·Status: COMPLETED ·Phase: NA
-
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
NCT03367767 ·Status: COMPLETED
-
Effects of Antioxidants on Human Macular Pigments
NCT00718653 ·Status: COMPLETED ·Phase: NA
-
Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine
NCT02113254 ·Status: TERMINATED ·Phase: NA
-
Macular Pigment and Glare Disability
NCT00909090 ·Status: COMPLETED ·Phase: NA
-
Visual Function and Ocular Pigmentation in Albinism
NCT00001153 ·Status: COMPLETED
-
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
NCT01915238 ·Status: COMPLETED
-
Intervention Trial in Early Age-related Macular Degeneration
NCT01694680 ·Status: COMPLETED ·Phase: NA